Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Apple Turns 50: From Garage Startup to AI Crossroads 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Shire to participate at two upcoming investor conferences
Lexington, MA, USA - September 7, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will present at the Bank of America Merrill Lynch Global Healthcare Conference 2017 on September 14, 2017 at 1:45 p.m. BST (8:45 a.m. EDT) and Jeff Poulton, Chief Financial Officer will participate at the Morgan Stanley Global Healthcare Conference on September 12, 2017 at 3:30 p.m. EDT (8:30 p.m. BST).
The live audio webcasts of both events will be available on Shire's Investor website at http://investors.shire.com/presentations-and-reports/quarterly-results-and-presentations. Subsequently, a replay of both events will be available on this same website
For further information please contact:
| Investor Relations | ||
| Ian Karp | [email protected] | +1 781 482 9018 |
| Robert Coates | [email protected] | +44 1256 894874 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
